Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program
Establishing an innovative class of polyomavirus antivirals spanning BK and JC virus indications CANTON, Mass.–(BUSINESS WIRE)–#BKV–Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus infections are a major cause … [Read more…]
